ZEFER
21.4.2022 10:02:12 CEST | Business Wire | Press release
Two pan-European projects have collaborated to bring zero emission hydrogen taxis and a new hydrogen refuelling station to the Danish capital city.
The ZEFER (Zero Emission taxi Fleets for European Rollout) and H2ME2 (Hydrogen Mobility Europe) projects, both funded by Europe’s Clean Hydrogen Partnership1 , have deployed 100 hydrogen taxis in Copenhagen with app-based taxi company DRIVR. The Toyota Mirais run on green hydrogen from renewable energy, following the installation and opening of a new hydrogen refuelling station (HRS) in the city.
This latest deployment of taxis means the wider ZEFER project has achieved its full complement of 180 FCEVs in high-utilisation, captive fleets across Europe with deployments in three capital cities (Paris, London and Copenhagen). The taxi deployment in Copenhagen will complement 60 taxis previously deployed to Hype by STEP in Paris, and 60 other passenger cars in London deployed between private-hire firm Green Tomato Cars (50) and the Metropolitan Police (10).
To date the 120 vehicles operated under the ZEFER project have driven over 7 million kilometres fuelled only by hydrogen. This high mileage is achieved as the project deliberately targets the very long daily mileage applications which are most suitable to hydrogen vehicles. They have achieved this without major safety or reliability incidents and vehicle performance has been rated highly by drivers and fleet managers, with limited breakdowns or issues encountered relating directly to the hydrogen drivetrain.
The Danish government have targeted all taxis to be zero emission by 2030 and DRIVR won the public tender to deliver ad-hoc taxi services in the City of Copenhagen. The 100 new hydrogen taxis will complement DRIVR's existing low emission fleet, already comprising hybrid, electric and hydrogen vehicles.
“We are incredibly proud that DRIVR has been entrusted with the important task of helping the municipality of Copenhagen reach its environmental goals, and we’re very grateful for the cooperation with Toyota, which has enabled us to meet their needs with the new Toyota Mirai hydrogen cars.” said Haydar Shaiwandi, CEO DRIVR.
“While aiming to deploy its platform in 15 new cities by 2024, Hype believes that hydrogen is one of the most relevant solutions for intensive and random mobility and that the taxi market can play a key role in accelerating the adoption of hydrogen by professionals at scale. We are glad to see DRIVR ramping up the integration of hydrogen among its solutions. This demonstrates that, thanks to the support of programmes such as ZEFER, an increasing number of players are taking the hydrogen path. Early adopters will definitely have an advantage and leverage their experience moving forward.” said Mathieu Gardies, President of Hype.
- Ends -
Notes to Editor
1 previously Fuel Cell and Hydrogen 2 Joint Undertaking (FCH2 JU)
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005150/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom